摘要:
Objective: To systematically evaluate the clinical efficacy and safety of Simiao Yong'an Decoction in the treatment of peripheral occlusive disease(PAOD). Methods: Eight randomized controlled clinical trials(RCT) of Simiao Yong'an Decoction in the treatment of PAOD were searched and screened from domestic and foreign databases (all from database construction to March 2020).The quality of the retrieved original studies was evaluated according to the evaluation criteria of Cochrane Handbook 5.1.0,and the included studies were meta-analyzed by RevMan5.3 software. Results: A total of 350 articles were retrieved,among which 14 studies met the inclusion criteria,with a total sample size of 1254 cases. The results of meta-analysis showed that:compared with conventional western Med,combined with Simiao Yong'an Decoction on the basis of western Med treatment can significantly improve the total clinical response rate of patients[RR=1.20,95%CI (1.14,1.27),P<0.00001],improve ankle brachial index(ABI) level[MD=0.79,95%CI (0.66,0.92),P<0.00001] and toe brachial index(TBI) level[RR=0.13,95%CI(0.10,0.16), P<0.00001],decreased c-reactive protein levels[MD=-8.55,95%CI(-8.99,-8.11),P< 0.00001] and LDL levels [MD=-0.41,95%CI(-0.62, -0.19),P=0.0002],and increased HDL levels[MD=0.32(0.22,0.43),P<0.00001].There was no statistically significant difference in the incidence of adverse reactions[RR=0.50]95%CI(1.15 ,1.64),P=0.25]. Conclusion: Simiao Yong'an Decoction combined with conventional western Med is more effective than conventional western Med in the treatment of PAOD.However,in view of the limitations of the quality of the analyzed literature,the positive results obtained in this study still need to be further verified by a large sample and multi-center clinical trial with a reliable research program.